FASN and metabolic syndrome: In addition, co-treatment with simvastatin further reduced dyslipidemia development in liver through down-regulating mRNA expression levels of fatty acid synthesis-related genes, such as Srebp1 and Fasn. It was interesting that a significant influence on olanzapine-induced inhibition of BAT thermogenesis was observed in O + S co-treatment group, especially the protein expression and the transcriptional levels of UCP1 and other core regulators of browning (PGC-1α), which was relevant with reduced weight gain and increased energy expenditure [43].